Lifesci Capital Issues Optimistic Outlook for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Lifesci Capital increased their Q2 2026 earnings estimates for shares of Larimar Therapeutics in a note issued to investors on Friday, May 15th. Lifesci Capital analyst F. Brisebois now forecasts that the company will earn ($0.48) per share for the quarter, up from their prior forecast of ($0.54). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.68) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.80) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.22.

Several other brokerages have also recently weighed in on LRMR. Wedbush dropped their price target on shares of Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Monday. Wall Street Zen raised shares of Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Tuesday, April 21st. Truist Financial raised shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Citigroup raised their price target on shares of Larimar Therapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Three research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $16.33.

Larimar Therapeutics Price Performance

LRMR stock opened at $3.24 on Tuesday. The stock has a market capitalization of $336.57 million, a PE ratio of -1.57 and a beta of 0.91. The company’s 50-day moving average is $4.57 and its 200-day moving average is $3.99. Larimar Therapeutics has a 1 year low of $1.80 and a 1 year high of $6.42.

Institutional Investors Weigh In On Larimar Therapeutics

Hedge funds have recently modified their holdings of the stock. AIGH Capital Management LLC raised its holdings in shares of Larimar Therapeutics by 100.0% in the 4th quarter. AIGH Capital Management LLC now owns 2,000,000 shares of the company’s stock worth $7,620,000 after purchasing an additional 1,000,000 shares during the period. Blue Owl Capital Holdings LP raised its holdings in shares of Larimar Therapeutics by 18.8% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 5,853,040 shares of the company’s stock worth $18,905,000 after purchasing an additional 925,000 shares during the period. Cantor Fitzgerald L. P. bought a new stake in shares of Larimar Therapeutics in the 3rd quarter worth approximately $412,000. Inceptionr LLC purchased a new position in Larimar Therapeutics in the 1st quarter valued at approximately $198,000. Finally, Strs Ohio grew its stake in Larimar Therapeutics by 174.7% in the 1st quarter. Strs Ohio now owns 21,700 shares of the company’s stock valued at $98,000 after buying an additional 13,800 shares in the last quarter. Institutional investors own 91.92% of the company’s stock.

Insider Activity at Larimar Therapeutics

In related news, Director James E. Flynn purchased 5,000,000 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were bought at an average price of $5.00 per share, with a total value of $25,000,000.00. Following the acquisition, the director owned 10,622,957 shares of the company’s stock, valued at $53,114,785. This trade represents a 88.92% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.50% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.